SHINE Grant to Boys & Girls Club

From left to right: SHINE CEO and Founder Greg Piefer; Boys & Girls Club Board President Matt Krueger and Executive Director Sara Stinski; and SHINE Community and Employee Engagement Manager Cheryl Peterson.

March 26, 2019 – Janesville, WI – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that it will grant the Boys & Girls Club of Janesville $5,000 for its new STEM Lab.

“Our Community Engagement Program was developed to enrich the Janesville and Rock County communities and support opportunities that align with our mission,” said SHINE Community and Employee Engagement Manager, Cheryl Peterson.  “This grant for the Club’s STEM Lab will allow the kids to experience valuable hands-on learning in science, technology, engineering and math (STEM) – a major focus of SHINE’s Community Engagement efforts.”

“We are really excited to move forward with this project,” said Matt Krueger, Board President for Boys & Girls Club of Janesville. “It is a major upgrade to the type of programming we will be able to offer our youth and is a great example of a community collaboration to bring real opportunities to underserved kids in Janesville.”

About the Boys & Girls Club of Janesville
The Boys & Girls Club of Janesville, located in downtown Janesville, serves 500 youth annually, with an average of 70 a day, with after school and summer programs that lead to academic achievement, healthy lifestyles, and good character and citizenship.

About Medical Isotopes
Medical isotopes are radioisotopes that are used in the diagnosis and treatment of disease. Molybdenum-99 (Mo-99) is a radioisotope that decays into the diagnostic imaging agent technetium‑99m (Tc-99m). The workhorse of nuclear medicine, Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce a variety of medical isotopes, including Mo‑99.Roughly 1% of all Mo-99 in the world decays every hour, meaning it must be continuously produced. Current production is limited to only a handful of government-owned nuclear research reactors, the majority of which are overseas.

About SHINE Medical Technologies, Inc.
Founded in 2010, SHINE is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for molybdenum-99. In 2014, SHINE announced the execution of molybdenum-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE molybdenum-99 can act as a drop-in replacement for reactor-based moly-99. In 2016, SHINE received regulatory approval to construct its facility from the Nuclear Regulatory Commission and signed a moly-99 supply agreement with HTA Co., Ltd., the largest Chinese distributor of radiopharmaceuticals. In 2017, SHINE built the first building on its Janesville campus: SHINE Building One.